TrademarkIQ íconeTrademarkIQ
Voltar para busca
Dado oficial do USPTO

SYNAPSINAE

Sabia que essa marca já está registrada no Estados Unidos?

Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.

Active USPTO registrationTipo: VerbalEscritório: US

Snapshot rápido

SYNAPSINAE

ST13

US500000087914101

Classe

5

Pedido

87914101

Registro

6303590

Diagnóstico de risco e oportunidade

Leitura executiva para decisão de naming, protocolo e monitoramento.

Atenção: há risco ativo

Situação USPTO

Active USPTO registration

Tipo de processo

Pedido e registro

Eventos registrados

47

Atualização mais recente

31/03/2026

Classificação

Registrada

Tipo de marca

Verbal

Classes Nice

5

Data de depósito

09/05/2018

Data de registro

30/03/2021

Data de expiração

-

Ação recomendada

Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.

Próximo passo

Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.

Dados completos do processo

Campos estruturados da autoridade responsável e do histórico oficial.

Data da situação

30/03/2021

Última transação

31/03/2026

Escritório responsável

United States Patent and Trademark Office

Código da situação

700

Cadastro oficial

Principal Register

Fundamento do pedido

Intent to use

Código do desenho

4

Tipo de titular

16

Localização do titular

GRAND CAYMAN, KY

Examinador

LIEBL, ALEXANDRA

Unidade examinadora

N20

Localização atual

PUBLICATION AND ISSUE SECTION

Titulares e representantes

Titulares

S. N. (pessoa física)
SyneuRx International (Taiwan) Corp.
SyneuRx International (Taiwan) Corp.

Representantes

Michael T. Smith BIRCH STEWART KOLASCH & BIRCH LLP

Classificação técnica

Classes Nice

Classe 5

Códigos Vienna

Sem códigos Vienna disponíveis.

Produtos e serviços

Classe 5

Therapeutic pharmaceutical for the treatment of neuropsychiatric disorders, namely, schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, bipolar disorder, and other central nervous system disorders; Syrups for pharmaceutical purposes for the treatment of ADHD; Chemical preparations for pharmaceutical or medical purposes, namely, for treating neuropsychiatric disorders, namely, schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, bipolar disorder, and other central nervous system disorders; Chemical reagents for medical or veterinary purposes; Adjuvants for medical purposes; Animal feed additive for use as a nutritional supplement for medical purposes; Amino acid preparations for medical purposes; Amino acids for medical or veterinary purposes; Amino acids for medical purposes; Beverages containing amino acid for use as a nutritional supplement; Liquid nutritional supplement; Amino acids for nutritional purposes; Dietary and nutritional supplements; Nutritional supplements in the form of capsules, tablets, caplets, powder, syrups, gummies and gels; Powdered nutritional supplement drink mix; Nutritional supplement meal replacement bars for boosting energy; Nutritional supplements consisting primarily of amino acid; Nutritional supplement shakes; Nutritional and dietary supplements formed and packaged as bars; Nutritional supplements in capsule form for dogs; Nutritional supplements; Nutritionally fortified water for medical purposes; Nutritionally fortified beverages for medical purposes; Vitamin fortified beverages for medical purposes; Vitamin enriched chewing gum for medical purposes; Soy protein for use as a nutritional supplement in various powdered and ready-to-drink beverages; Nutritional supplement in the nature of a nutrient-dense, protein-based drink mix; Powdered nutritional supplement drink mix containing amino acid; Nutritional supplements for cats, dogs; Nutraceuticals for use as a dietary supplement for depressed mood; Nutraceuticals for the treatment of CNS disorders; Nutraceuticals for use as a dietary supplement

Publicações

Histórico de despachos e eventos da marca no USPTO.

47 publicações encontradas

REM1

COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED

30/03/2026

ASGN

AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP

21/01/2026

R.PR

REGISTERED-PRINCIPAL REGISTER

30/03/2021

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

12/01/2021

PUBO

PUBLISHED FOR OPPOSITION

12/01/2021

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

23/12/2020

OTHE

CASE RETURNED TO EXAMINATION

09/12/2020

IUCN

NOTICE OF ALLOWANCE CANCELLED

09/12/2020

ATRQ

ATTORNEY REVIEW/DECISION ON AMENDMENT REQUIRED

02/12/2020

PCBG

PETITION TO DIRECTOR - CHANGE BASIS - GRANTED

02/12/2020

APET

ASSIGNED TO PETITION STAFF

01/12/2020

DOCK

ASSIGNED TO EXAMINER

02/11/2020

TPAD

TEAS PETITION TO AMEND BASIS RECEIVED

01/10/2020

CHAN

APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED

24/07/2020

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

24/07/2020

ECDR

TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS

24/07/2020

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

24/07/2020

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

24/07/2020

COAR

TEAS CHANGE OF OWNER ADDRESS RECEIVED

24/07/2020

EXRA

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

30/05/2020

EX3G

SOU EXTENSION 3 GRANTED

28/05/2020

EXT3

SOU EXTENSION 3 FILED

28/05/2020

EEXT

SOU TEAS EXTENSION RECEIVED

28/05/2020

EXRA

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

05/12/2019

EX2G

SOU EXTENSION 2 GRANTED

03/12/2019

EXT2

SOU EXTENSION 2 FILED

03/12/2019

EEXT

SOU TEAS EXTENSION RECEIVED

03/12/2019

EXRA

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

11/06/2019

EX1G

SOU EXTENSION 1 GRANTED

07/06/2019

EXT1

SOU EXTENSION 1 FILED

07/06/2019

EEXT

SOU TEAS EXTENSION RECEIVED

07/06/2019

NOAM

NOA E-MAILED - SOU REQUIRED FROM APPLICANT

25/12/2018

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

30/10/2018

PUBO

PUBLISHED FOR OPPOSITION

30/10/2018

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

10/10/2018

ALIE

ASSIGNED TO LIE

21/09/2018

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

06/09/2018

XAEC

EXAMINER'S AMENDMENT ENTERED

06/09/2018

GNEN

NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED

06/09/2018

GNEA

EXAMINERS AMENDMENT E-MAILED

06/09/2018

CNEA

EXAMINERS AMENDMENT -WRITTEN

06/09/2018

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

05/09/2018

GNRT

NON-FINAL ACTION E-MAILED

05/09/2018

CNRT

NON-FINAL ACTION WRITTEN

05/09/2018

DOCK

ASSIGNED TO EXAMINER

30/08/2018

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

18/05/2018

NWAP

NEW APPLICATION ENTERED

12/05/2018

Proteção contínua da sua marca

Seja avisado a cada novo depósito que ameace SYNAPSINAE ou a sua marca.

Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.